Integra LifeSciences Holdings Corporation (IART)
Healthcare · NMS
Price as at 1 Oct 2026, 09:07 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Integra LifeSciences Holdings Corporation trades at $16.28, which is 18% above the $13.40 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 31 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
IART earnings and analyst estimates
Recommendation mix, 11 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
IART passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$25.86M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$9.11M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$6.28M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$4.64M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$3.32M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in IART
Trades in IART disclosed by members of Congress and executive-branch officials, latest first:
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 10 Mar 2020 · disclosed 16 Apr 2020
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 10 Feb 2020 · disclosed 10 Mar 2020
- Donna Shalala · HouseSell · $1,001 - $15,000 · traded 9 Jan 2019 · disclosed 27 Apr 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
IART peers
The largest companies in the same industry (Medical Devices), then in the same sector.
- PHG Koninklijke Philips N.V.
- PEN Penumbra, Inc.
- GMED Globus Medical, Inc.
- BIO Bio-Rad Laboratories, Inc.
- LIVN LivaNova PLC
- IRTC iRhythm Holdings, Inc.
- TMDX TransMedics Group, Inc.
- NEOG Neogen Corporation
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Integra LifeSciences Holdings Corporation (IART) undervalued?
Against our fair value estimate of $13.40, IART at $16.28 is 18% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own IART?
7 of the institutions we track reported a position in IART in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its IART data?
Fundamentals for IART come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 09:07 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for IART, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.